US20260108627A1 mRNA Lipid Nanoparticle Compositions for Hypercholesterolemia and Cardiovascular Disease Treatment
Summary
The USPTO published application US20260108627A1 on April 23, 2026, disclosing compositions and methods for treating hypercholesterolemia and/or cardiovascular disease using lipid nanoparticle delivery systems for mRNA-based therapeutics. The application names six inventors: Fuxin Shi, Wenhu Cao, Ye Chen, Huanle Liu, Han Qiu, and Leqi Liao, with a filing date of September 21, 2023. CPC classifications include A61K 48/005, A61P 3/06, C12N 9/226, and C12N 15/111, indicating lipid nanoparticle formulations and gene therapy approaches.
“Compositions and methods are described herein for treating subjects having hypercholesterolemia and/or cardiovascular disease.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 215 changes logged to date.
What changed
The USPTO published application US20260108627A1 disclosing compositions and methods for treating hypercholesterolemia and/or cardiovascular disease. The application covers lipid nanoparticle delivery systems incorporating mRNA therapeutics, with CPC classifications spanning A61K 48/005 (gene therapy vectors) and C12N 15/111 (nucleic acid sequences). The publication includes nine CPC codes indicating a multi-faceted therapeutic approach.
For pharmaceutical and biotechnology companies developing mRNA-based cardiovascular therapies, this published application establishes prior art that may affect freedom-to-operate analyses. Competitors in the lipid nanoparticle and gene therapy space should review the disclosed formulations and methods for potential overlap with their own development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR CARDIOVASCULAR DISEASE
Application US20260108627A1 Kind: A1 Apr 23, 2026
Inventors
Fuxin Shi, Wenhu Cao, Ye Chen, Huanle Liu, Han Qiu, Leqi Liao
Abstract
Compositions and methods are described herein for treating subjects having hypercholesterolemia and/or cardiovascular disease.
CPC Classifications
A61K 48/005 A61K 9/1271 A61K 9/5123 A61K 48/0083 A61P 3/06 C12N 9/226 C12N 15/111 C12N 15/88 C12N 2310/20
Filing Date
2023-09-21
Application No.
19113964
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.